Drug Search Results
More Filters [+]

STM-01

Alternative Names: STM-01, STM 01, STM01
Latest Update: 2024-09-17
Latest Update Note: News Article

Product Description

STM-01 has proven superior to all other stem cell therapeutics in restoring cardiac function in animals following an induced heart attack, reflecting an ability to halt or reverse the inflammation, apoptosis, and other processes that compromise heart function in this model. The results below compare STM-01 to vehicle (IMDM), cardiosphere-derived cells (CDC), adult MSCs, adult cardiac progenitor cells (BM-MSC), and umbilical cord blood derived MSCs (UCBC). (Sourced from: https://secretometherapeutics.com/pipeline/)

Mechanisms of Action: Stem Cell Therapy

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Secretome Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for STM-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events